Changes to the Code
H.R. 5467 · PAAT Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1395w–104 Beneficiary protections for qualified prescription drug coverage
3 changes the bill asks for here, 2 carried out
- Carried out:
in subsection (b)(3), by adding at the end the following new subparagraph:
(J) Required inclusion of certain drugs for autoimmune diseases and blood disorders.— (i) In general.— For 2027 and each subsequent year, a PDP sponsor offering a prescription drug plan shall include each covered part D drug that is an autoimmune or blood disorder drug described …
- Not carried out:
by redesignating paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (Public Law 115–123), as paragraph (7); and
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: redesignating paragraph (X), as added by section N of division e of the bipartisan budget act of N (REF), as paragraph (X); and - Carried out:
by adding at the end the following new paragraph:
(8) Prohibition on use of prior authorization for certain autoimmune or blood disorder drugs.— For plan years beginning on or after January 1, 2027, a PDP sponsor offering a prescription drug plan (and an MA organization offering an MA–PD plan) may not require, with respect to …
§ 1395w–104(b)Access to covered part D drugs(3)–(4)
Start of § 1395w–104 to (b)(3)(I) unchanged ·
(i) In general For 2026 and each subsequent year, the PDP sponsor offering a prescription drug plan shall include each covered part D drug that is a selected drug under section 1320f–1 of this title for which a maximum fair price (as defined in section 1320f(c)(3) of this title) is in effect with respect to the year.
(ii) Clarification Nothing in clause (i) shall be construed as prohibiting a PDP sponsor from removing such a selected drug from a formulary if such removal would be permitted under section 423.120(b)(5)(iv) of title 42, Code of Federal Regulations (or any successor regulation).
(J) [inserted: Required inclusion of certain drugs for autoimmune diseases and blood disorders.—]
(i) [inserted: In general.—] [inserted: For 2027 and each subsequent year, a PDP sponsor offering a prescription drug plan shall include each covered part D drug that is an autoimmune or blood disorder drug described in clause (ii).]
(ii) [inserted: Autoimmune or blood disorder drug.—] [inserted: For purposes of clause (i), a drug described in this clause is a covered part D drug indicated and prescribed for the treatment of an autoimmune disease, hemophilia, or Von Willebrand disease.]
(4) Ensuring access during COVID–19 public health emergency period
(A) In general During the emergency period described in section 1320b–5(g)(1)(B) of this title, subject to subparagraph (B), a prescription drug plan or MA–PD plan shall, notwithstanding any cost and utilization management, medication therapy management, or other such programs under this part, permit a part D eligible individual enrolled in such plan to obtain in a single fill or refill, at the option of such individual, the total day supply (not to exceed a 90-day supply) prescribed for such individual for a covered part D drug.
§ 1395w–104(c)–(e)
(b)(4)(B)–(c)(6)(C) unchanged ·
(v) For any other purpose that the Secretary determines is necessary to include in order to protect the identity of individuals entitled to, or enrolled for, benefits under this subchapter and to protect the security of personal health information.
(D) Data described The data described in this clause are standardized extracts (as determined by the Secretary) of claims data under parts A and B for items and services furnished under such parts for time periods specified by the Secretary. Such data shall include data as current as practicable.
(8) [inserted: Prohibition on use of prior authorization for certain autoimmune or blood disorder drugs.—] [inserted: For plan years beginning on or after January 1, 2027, a PDP sponsor offering a prescription drug plan (and an MA organization offering an MA–PD plan) may not require, with respect to an individual enrolled under such plan, that prior authorization for an autoimmune or blood disorder drug (as described in subsection (b)(3)(J)(ii)) be obtained more than once during any 12-month period unless such drug is—]
(A) [inserted: typically used for a period of 12 months or less;]
(B) [inserted: an opioid, a benzodiazepine, a barbiturate, or carisoprodol; or]
(C) [inserted: a drug with respect to which a risk evaluation and mitigation strategy is required under Section 505–1 of the Federal Food, Drug, and Cosmetic Act.]
(d) Consumer satisfaction surveys In order to provide for comparative information under section 1395w–101(c)(3)(A)(v) of this title, the Secretary shall conduct consumer satisfaction surveys with respect to PDP sponsors and prescription drug plans in a manner similar to the manner such surveys are conducted for MA organizations and MA plans under part C.
(e) Electronic prescription program
Rest of § 1395w–104 unchanged ·